To join a prostate cancer clinical trial in United States, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United States directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.

What phases are prostate cancer trials in United States?

Active prostate cancer trials in United States span Phase 1, Phase 2, Phase 1, Phase 2, Phase 2, Phase 3, Phase 3, Phase 4. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.

Browse More

All United States Trials → Global prostate cancer Trials → All Countries → All Trials →

Active Trials in United States (47)

Precision-Based Genomics in Prostate Cancer

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Collection of Blood From Patients With Prostate Cancer

High Intensity Focused Ultrasound in Prostate Cancer

Evaluating Tolerability of ePUHRT With Brachytherapy Boost

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

CV CARE: CardioVascular Care in PC Patients

Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

Investigation of Impact of AI on Prostate Cancer Workflow

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

Mechanisms of Resistance to PSMA Radioligand Therapy

Micro-UltraSound In Cancer - Active Surveillance

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots

A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Outcomes of Focal Ablation for Prostate Cancer

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

SBRT Boost for Unfavorable Prostate Cancer'

Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PSMA-PET to Guide Prostatectomy

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

EDRN Prostate MRI Biomarker Study

The Florida ASCENT Study

Two Fraction Prostate SBRT With DIL SIB

Frequently Asked Questions